Moreover, type I IFN administration shortly after MERS-CoV challenges in mice, protected mice from lethal infection even in a scenario of decreased ISGs and inflammatory cytokine gene expression, contrasting with failure and side-effects elicited by delayed IFN delivery (86). Here, IFNA1 is linked to infection.